Mindray Medical International Limited (NYSE: MR) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Mindray Medical International Limited met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share dropped.

Margins contracted across the board.

Revenue details
Mindray Medical International Limited notched revenue of $219.0 million. The four analysts polled by S&P Capital IQ expected net sales of $217.5 million on the same basis. GAAP reported sales were 21% higher than the prior-year quarter's $180.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.34. The three earnings estimates compiled by S&P Capital IQ anticipated $0.38 per share. GAAP EPS of $0.31 for Q1 were 3.1% lower than the prior-year quarter's $0.32 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 54.9%, 20 basis points worse than the prior-year quarter. Operating margin was 16.8%, 150 basis points worse than the prior-year quarter. Net margin was 16.7%, 410 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $259.5 million. On the bottom line, the average EPS estimate is $0.47.

Next year's average estimate for revenue is $1.05 billion. The average EPS estimate is $1.79.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,373 members out of 1,408 rating the stock outperform, and 35 members rating it underperform. Among 318 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 305 give Mindray Medical International Limited a green thumbs-up, and 13 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International Limited is outperform, with an average price target of $32.42.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Mindray Medical International Limited performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.